MDMA, serotonergic neurotoxicity, and the diverse functional deficits of recreational 'Ecstasy' users

Neuroscience and Biobehavioral Reviews

Volumn 37, Issue 8, 2013, Pages 1466-1484

  Parrott, Andrew C ^a,b  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b SWINBURNE UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

Cognition; Ecstasy; MDMA; Memory; Neurotoxicity; Psychobiology; Serotonin; SERT

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; SEROTONIN; SEROTONIN TRANSPORTER;

APPETITE; CHILD DEVELOPMENT; COGNITION; COMPLEX COGNITION; DECLARATIVE MEMORY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; EVOKED RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HIPPOCAMPUS; HORMONE ACTION; HUMAN; IMMUNOCOMPETENCE; INTELLIGENCE QUOTIENT; MENTAL HEALTH; MOOD; NEUROIMAGING; NEUROTOXICITY; NOCICEPTION; NONHUMAN; OXIDATIVE STRESS; PARIETAL CORTEX; PREFRONTAL CORTEX; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; PROCEDURAL MEMORY; PROSPECTIVE MEMORY; PROTEIN BINDING; PSYCHOBIOLOGY; PSYCHOMOTOR PERFORMANCE; REVIEW; SEROTONERGIC NEUROTOXICITY; SEROTONINERGIC SYSTEM; SIMPLE COGNITION; SKILL; SLEEP; SUBSTANCE ABUSE; TREMOR; VISION; WITHDRAWAL SYNDROME; WORKING MEMORY;

COGNITION; ECSTASY; MDMA; MEMORY; NEUROTOXICITY; PSYCHOBIOLOGY; SEROTONIN; SERT;

AMPHETAMINE-RELATED DISORDERS; COGNITION; COGNITION DISORDERS; HUMANS; MEMORY; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; NEUROTOXICITY SYNDROMES; STREET DRUGS;

EID: 84879725463     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2013.04.016     Document Type: Review

References (197)

1. Adamaszek M., Khaw A.V., Buck U., Andresen B., Thomasius R. Evidence of neurotoxicity of ecstasy: sustained effects on electroencephalographic activity in polydrug users. PLoS One 2010, 5. e14097.
2. Alati R., Kinner S.A., Hayatbakhsh M.R., Mamun A.A., Najman J.M., Williams G.M. Pathways to ecstasy use in young adults: anxiety, depression or behavioural deviance?. Drug Alc. Depend. 2008, 92:108-115.
3. Allen R.P., McCann U.D., Ricaurte G.A. Persistent effects of (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") on human sleep. Sleep 1993, 16:560-564.
4. Angelucci F., Ricci V., Martinotti G., Palladino I., Spalletta G., Caltagirone C., Bria P. Ecstasy (MDMA)-addicted subjects show increased serum levels of brain-derived neurotrophic factor, independently from a rise in drug-induced psychotic symptoms. Addict. Biol. 2010, 15:365-367.
5. Back-Madruga C., Boone K.B., Chang L., Grob C.S., Lee A., Nations H., Poland R.E. Neuropsychological effects of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) in recreational users. Clin. Neuropsychol. 2003, 17:446-459.
6. Banks M.L., Sprague J.E., Czoty P.W., Nader M.A. Effects of ambient temperature on the relative reinforcing strength of MDMA using a choice procedure in monkeys. Psychopharmacology (Berl.) 2008, 196:63-70.
7. Bauernfeind A.L., Dietrich M.S., Blackford J.U., Charboneau E.J., Lillevig J.G., Cannistraci C.J., Woodward N.D., Cao A., Watkins T., Di Iorio C.R., Cascio C., Salomon R.M., Cowan R.L. Human Ecstasy use is associated with increased cortical excitability: an fMRI study. Neuropsychopharmacology 2011, 36:1127-1141.
8. Baumann M.H., Rothman R.B. Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA). Int. Rev. Neurobiol. 2009, 88:257-296.
9. Bedi G., Redman J. Recreational ecstasy use: acute effects potentiated by ambient conditions?. Neuropsychobiology 2006, 53:113.
10. Benningfield M.M., Cowan R.L. Brain serotonin function in MDMA (Ecstasy) users: evidence for persistent neurotoxicity. Neuropsychopharmacol. Rev. 2013, 38:253-255.
11. Berger U.V., Gu X.F., Azmitia E.C. The substituted amphetamines 3,4 methylenedioxymethamphetamine, methamphetamine, para-chloroamphetamine and fenfluramine induce 5-hydroxytrypamine release via a common mechanism blocked by fluoxetine and cocaine. Eur. J. Pharmacol. 1992, 215:153-160.
12. Biezonski D.K., Meyer J.S. The nature of 3, 4-methylenedioxymethamphetamine (MDMA)-induced serotonergic dysfunction: evidence for and against the neurodegeneration hypothesis. Curr. Neuropharmacol. 2011, 9:84-90.
13. Blagrove M., Seddon J., George S., Parrott A.C., Stickgold R., Walker M.P., Jones K.A., Morgan M.J. Procedural and declarative memory task performance, and the memory consolidation function of sleep, in recent and abstinent ecstasy/MDMA users. J. Psychopharmacol. 2011, 25:465-477.
14. Bolla K.I., McCann U.D., Ricaurte G.A. Memory impairment in abstinent MDMA (Ecstasy") users. Neurology 1998, 51:1532-1537.
15. Bosch O.G., Wagner M., Jessen F., Kuhn Z.W., Joe A., Seifritz E., Maier W., Biersack H.-J., Quednow B.-B. Verbal memory deficits are correlated with prefrontal hypometabolism in 18FDG PET of recreational MDMA users. PLoS One 2013, 8. e61234.
16. Bousman C.A., Cherner M., McEmory K.T., Barron D., Grebenstein P., Atkinson J.H., Heaton R.K., Grant I. Preliminary evidence of motor impairment among polysubstance 3,4-methylenedioxymethamphetamine users with intact neuropsychological functioning. J. Int. Neuropsychol. Soc. 2010, 16:1047-1055.
17. Boyle N.T., Connor T.J. Methylenedioxymethamphetamine ('Ecstasy')-induced immunosuppression: a cause for concern?. Br. J. Pharmacol. 2010, 161:17-32.
18. Brière F.N., Fallu J.S., Janosz M., Pagani L.S. Prospective associations between meth/amphetamine (speed) and MDMA (ecstasy) use and depressive symptoms in secondary school students. J. Epidemiol. Commun. Health 2012, 66:990-994.
19. Buchert R., Thiele F., Thomasius R., Wilke F., Petersen K., Brenner W., Mester J., Spies L., Clausen M. Ecstasy induced reduction of the availability of the brain serotonin transporter as revealed by [11C] (+) McN5652-PET and the multi-linear reference tissue model: loss of transporter or artifact of tracer kinetic modelling?. J. Psychopharmacol. 2007, 21:628-634.
20. Buchert R., Thomasius R., Nebeling B., Petersen K., Obrocki J., Jenicke L., Wilke F., Wartberg L., Zapletalova P., Clausen M. Long-term effects of ecstasy" use on serotonin transporters of the brain investigated by PET. J. Nucl. Med. 2003, 44:375-384.
21. Burgess A.P., Venables L., Jones H., Edwards R., Parrott A.C. Event related potential (ERP) evidence for selective impairment of verbal recollection in abstinent recreational methylenedioxymethamphetamine (Ecstasy")/polydrug users. Psychopharmacology (Berl) 2011, 216:545-556.
22. Casco C., Forcella M., Beretta G., Grieco A., Campana G. Long-term effects of MDMA (Ecstasy) on the human central nervous system revealed by visual evoked potentials. Add. Biol. 2005, 10:187-195.
23. Cottler L.B., Womack S.B., Compton W.M., Ben-Abdallah A. Ecstasy abuse and dependence: applicability and reliability of DSM-IV criteria among adolescents and young adults. Hum. Psychopharmacol. 2001, 16:599-606.
24. Connor T.J. Methylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system. Immunology 2004, 111:357-367.
25. Cornish J.L., Shahnawaz Z., Thompson M.R., Wong S., Morley K.C., Hunt G.E., McGregor I.S. Heat increases 3,4-methylenedioxymethamphetamine self-administration and social effects in rats. Eur. J. Pharmacol. 2003, 482:339-341.
26. Cowan P.J., Lucki I. Serotonin revisited. Psychopharmacology (Berl) 2011, 213:167-169.
27. Cowan R.L., deB Frederick B., Haga E., Rohan M., Levin J., Renshaw P.F., Lucas S.E. Visual cortex activation using the fMRI BOLD method in human MDMA (ecstasy) users. MDMA/Ecstasy Research: Advances, Challenges, and Future Directions 2001, 46. (Conference Abstract).
28. Cowan R.L., Haga E., deB Frederick B., Dietrich M.S., Vimal R.L., Lucas S.E., Renshaw P.F. MDMA use is associated with increased spatial BOLD fMRI visual cortex activation in human MDMA users. Pharmacol. Biochem. Behav. 2006, 84:219-228.
29. Cowan R.L. Neuroimaging research in human MDMA users: a review. Psychopharmacology (Berl) 2007, 189:539-556.
30. Croft R.J., Mackay A.J., Mills A.T.D., Gruzelier J.G.H. Electrophysiological evidence of serotonergic impairment in long-term MDMA (Ecstasy) users. Am. J. Psychiatry 2001, 158:1687-1692.
31. Curran H.V., Robjant K. Eating attitudes, weight concerns, and beliefs about drug effects in women who use ecstasy. J. Psychopharm. 2006, 20:425-431.
32. Curran H.V., Travill R.A. Mood and cognitive effects of 3, 4-methylenedioxymethamphetamine (MDMA, ecstasy): weekend high followed by mid-week low. Addiction 1997, 92:821-831.
33. Curran H.V., Verheyden S.L. Altered response to tryptophan supplementation after long-terms abstention from MDMA (ecstasy) is highly correlated with human memory function. Psychopharmacology (Berl) 2003, 169:91-103.
34. Dafters R.I., Duffy F., O'Donnell P.J., Bouquet C. Level of use of 3,4-methylenedioxymethamphetamine (MDMA or Ecstasy) in humans correlates with EEG power and coherence. Psychopharmacology (Berl) 1999, 145:82-90.
35. Dastrup E., Lees M.N., Bechara A., Dawson J.D., Rizzo M. Risky car following in abstinent users of MDMA. Accid. Anal. Prevent. 2010, 42:867-873.
36. Daumann J., Fischermann T., Heekeren K., Henke K., Thron A., Gouzoulis-Mayfrank E. Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) 2005, 180:607-611.
37. Daumann J., Till B., Fischermann T., Rezk M., Gouzoulis-Mayfrank E. Intensity dependence of auditory evoked dipole source activity in polydrug ecstasy users: evidence from an 18 months longitudinal study. J. Psychopharmacol. 2006, 20:236-244.
38. Degenhardt L., Hall W. The health and psychological effects of ecstasy (MDMA) use. NDARC Monograph no. 62 2009, University of New South Wales, Australia.
39. De Sola S., Tarancón T., Peña-Casanova J., Espadaler J.M., Langohr K., Poudevida S., Farré M., Verdejo-García A., de la Torre R. Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study. Psychopharmacology (Berl) 2008, 200:425-437.
40. de Win M.M., Jager G., Booij J., Reneman L., Schilt T., Lavini C., Olabarriaga S.D., den Heeten G.J., van den Brink W. Sustained effects of ecstasy on the human brain: a prospective neuroimaging study in novel users. Brain 2008, 131:2936-2945.
41. Di Iorio C.R., Watkins T.J., Dietrich M.S., Cao A., Blackford J.U., Rogers B., Ansari M.S., Baldwin R.M., Li R., Kessler R.M., Salomon R.M., Benningfield M., Cowan R.L. Evidence for chronically altered serotonin function in the cerebral cortex of female 3,4-methylenedioxymethamphetamine polydrug users. Arch. Gen. Psychiatry 2012, 69:399-409.
42. Dickson C., Bruno R., Brown J. Investigating the role of serotonin in visual orientation processing using an 'ecstasy' (MDMA)-based research model. Neuropsychobiology 2009, 60:204-212.
43. Dumont G.J., Verkes R.J. A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers. J. Psychopharmacol. 2006, 20:176-187.
44. Erritizoe D., Frokjaer V.G., Holst K.K., Christoffersen M., Johansen S.S., Svarer C., Madsen J., Rasmussen P.M., Ramsoy T., Jernigan T.L., Knudsen G.M. In vivo imaging of cerebral serotonin transporter and serotonin (2A) receptor binding in 3,4-methylenedioxymethamphetamine (MDMA or ecstasy) and hallucinogen users. Arch. Gen. Psychiatry 2011, 68:562-576.
45. Fisk J.E., Montgomery C., Wareing M., Murphy P.N. Reasoning deficits in ecstasy (MDMA) polydrug users. Psychopharmacology (Berl) 2005, 181:550-559.
46. Flavel S.C., Koch J.D., White J.M., Todd G. Illicit stimulant use in humans is associated with long-term increases in tremor. PLoS One 2012, 7. e52025.
47. Fox H., Parrott A.C., Turner J.J.D. Ecstasy/MDMA related cognitive deficits: a function of dosage rather than awareness of problems. J. Psychopharm. 2001, 15:273-281.
48. Fox H.C., McLean A., Turner J.J.D., Parrott A.C., Rogers R., Sahakian B.J. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA (ecstasy") polydrug users. Psychopharmacology (Berl) 2002, 162:203-214.
49. Freedman R.R., Johanson C.E., Tancer M.E. Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2005, 183:248-256.
50. Gamma A., Buck A., Berthold T., Vollenweider F.X. No difference in brain activation during cognitive performance between Ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a positron emission tomography study. J. Clin. Psychopharmacol. 2001, 21:66-71.
51. Gamma A., Brandeis D., Brandeis R., Vollenweider F.X. The P3 in 'ecstasy' polydrug users during response inhibition and execution. J. Psychopharmacol. 2005, 19:504-512.
52. Gerra G., Zaimovic A., Giucastro G., Maestri D., Monica C., Sartori R., Caccavari R., Delsignore R. Serotonergic function after 3,4-methylenedioxy-methamphetamine (Ecstasy) in humans. Int. Clin. Psychopharmacol. 1998, 13:1-9.
53. Gerra G., Zaimovic A., Ferri M., Zambelli U., Timpano M., Neri E., Marzocchi G.F., Delsignore R., Brambilla F. Long-lasting effects of 3,4-methylenedioxymethamphetamine (ecstasy) on serotonin system functions in humans. Biol. Psychiatry 2000, 47:127-136.
54. Gerra G., Zaimovic A., Ampollini P., Giusti F., Delsignore R., Raggi M.A., Laviola G., Macchia T., Brambilla F. Experimentally induced aggressive behaviours in subjects with 3,4-methylenedioxy-methamphetamine (Ecstasy) use history: psychobiological correlates. J. Subst. Abuse 2001, 13:471-491.
55. Gerra G., Bassignana S., Zaimovic A., Moi G., Bussandri M., Caccavari C., Brambilla F. Hypothalamic-pituitary-adrenal axis responses to stress in subjects with 3,4-methylenedioxy-methamphetamine ('ecstasy') use history: correlation with dopamine receptor sensitivity. Psychiatry Res. 2003, 120:115-124.
56. Goldstein R.Z., Craig A.D., Bechara A., Garavan H., Childress A.R., Palurs M.P., Volow N.D. The neurocircuitry of impaired insight in drug addiction. Trends Cogn. Sci. 2009, 13:372-380.
57. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J., Fimm B., Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol. Neurosurg. Psychiatry 2000, 68:719-725.
58. Gouzoulis-Mayfrank E., Daumann J. Neurotoxicity of drugs of abuse--the case of methylenedioxyamphetamines (MDMA, ecstasy), and amphetamines. Dialogues Clin. Neurosci. 2009, 11:305-317.
59. Green A.R., Cross A.J., Goodwin G.M. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or ecstasy). Psychopharmacology (Berl) 1995, 119:247-260.
60. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, ecstasy). Pharmacol. Rev. 2003, 55:463-508.
61. Greer G., Tolbert R. Subjective reports of the effects of MDMA in a clinical setting. J. Psychoact. Drugs 1986, 18:319-327.
62. Gunnarsson M., Fahlke C., Balldin J. Adolescents who have tried illicit drugs and experienced psychiatric symptoms seldom seek professional help. A pilot study of 18-year old high school students in an urban district. Lakartidningen 2004, 101:1280-1282.
63. Hadjiefthyvoulou F., Fisk J.E., Montgomery C., Bridges N. Everyday and prospective memory deficits in ecstasy/polydrug users. J. Psychopharmacol. 2011, 25:453-464.
64. Hadjiefthyvoulou F., Fisk J.E., Montgomery C., Bridges N. Prospective memory functioning among ecstasy/polydrug users: evidence from the Cambridge Prospective Memory Test (CAMPROMPT). Psychopharmacology (Berl) 2011, 215:761-774.
65. Halpern J.H., Pope H.G., Sherwood A.R., Barry S., Hudson J.I., Yurgelun-Todd D. Residual effects of illicit 3,4-methylenedioxymethamphetamine in individuals with minimal exposure to other drugs. Drug Alc. Depend. 2004, 75:135-147.
66. Halpern J.H., Sherwood A.R., Hudson J.I., Gruber S., Kozin D., Pope H.G. Residual features of long term ecstasy use with minimal exposure to other drugs. Addiction 2011, 106:777-786.
67. Halpern P., Moskovich J., Avrahami B., Bentur Y., Soffer D., Peleg K. Morbidity associated with MDMA (ecstasy) abuse - a survey of emergency department admissions. Hum. Exp. Toxicol. 2011, 30:259-266.
68. Hanson K.L., Luciana M. Neurocognitive function in users of MDMA: the importance of clinically significant patterns of use. Psychol. Med. 2004, 34:229-246.
69. Harris D.S., Baggott M., Mendelson J.H., Mendelson J.E., Jones R.T. Subjective and hormonal effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology (Berl) 2002, 162:396-405.
70. Heekeren K., Daumann J., Geyer M.A., Gouzoulis-Mayfrank E. Plasticity of the acoustic startle reflex in currently abstinent ecstasy (MDMA) users. Psychopharmacology (Berl) 2004, 173:418-424.
71. Heffernan T.M., Ling J., Scholey A.B. Subjective ratings of prospective memory deficits in MDMA ('ecstasy') users. Hum. Psychopharmacol. 2001, 16:339-344.
72. Heffernan T.M., Jarvis H., Rodgers J., Scholey A.B., Ling J. Prospective memory, everyday cognitive failures, and central executive function in recreational users of ecstasy. Hum. Psychopharmacol. 2001, 16:607-612.
73. Heninger G.R. The role of serotonin in clinical disorders. Psychopharmacology: A Fourth Generation of Progress 1995, 471-482. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
74. Hopper J.W., Su Z., Looby A.R., Ryan E.T., Penetar D.M., Palmer C.M., Lukas S.E. Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: an ecological momentary assessment study. Drug Alcohol Depend. 2006, 85:221-235.
75. Huether G., Zhou D., Ryuther E. Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4 methylenedioxymethamphetamine (MDMA, ecstasy") and its congeners. J. Neural Transm. 1997, 104:771-794.
76. Huizink A.C., Ferdinand R.F., van der Ende J., Verhulst F.C. Symptoms of anxiety and depression in childhood and use of MDMA: prospective population based study. Brit. Med. J. 2006, 322:825-828.
77. Jacobs B.L., Fornal C.A. Serotonin and behaviour: a general hypothesis. Psychopharmacology: A Fourth Generation of Progress 1995, 461-470. Raven Press, New York. F.E. Bloom, D.J. Kupfer (Eds.).
78. Jacobsen L.K., Mencl W.E., Pugh K.R., Skudlarski P., Krystal J.H. Preliminary evidence of hippocampal dysfunction in adolescent MDMA (ecstasy) users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) 2004, 173:383-390.
79. Jansen K.L.R. Ecstasy (MDMA) dependence. Drug Alcohol Depend. 1999, 53:121-124.
80. Kalant H. The pharmacology and toxicology of ecstasy" (MDMA) and related drugs. Can. Med. Assn. J. 2001, 165:17-28.
81. Karageorgiou J., Dietrich M.S., Charboneau E.J., Woodward N.D., Blackford J.U., Salomon R.M., Cowan R.L. Prior MDMA (Ecstasy) use is associated with increased basal ganglia-thalamocortical circuit activation during motor task performance in humans: an fMRI study. Neuroimage 2009, 46:817-826.
82. Kish S.J., Furukawa Y., Ang L., Vorce S.P., Kalasinsky K.S. Striatal serotonin is depleted in brain of a human MDMA (Ecstasy) user. Neurology 2000, 55:294-296.
83. Kish S.J. How strong is the evidence that brain serotonin neurons are damaged in human users of ecstasy?. Pharmacol. Biochem. Behav. 2002, 71:845-855.
84. Kish S.J., Lerch J., Furukawa Y., Tong J., McCluskey T., Wilkins D., Houle S., Meyer J., Mundo E., Wilson A.A., Rusjan P.M., Saint-Cyr J.A., Guttman M., Collins D.L., Shapiro C., Warsh J.J., Boileau I. Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study. Brain 2010, 133:1779-1797.
85. Krystal J.H., Price L.H., Opsahl C., Ricaurte G.A., Heninger G.R. Chronic 3,4-methylenedioxymethamphetamine (MDMA) use: effects on mood and neuropsychological function?. Am. J. Drug Alc. Abuse 1992, 18:331-341.
86. Laws K.R., Kokkalis J. Ecstasy (MDMA) and memory function: a meta-analytic update. Hum. Psychopharmacol. 2007, 22:381-388.
87. Lieb R., Schuetz C.G., Pfister H., von Sydow K., Wittchen H.-U. Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alc. Depend 2002, 68:195-207.
88. MacInnes N., Handley S.L., Harding G.F.A. Former chronic methylenedioxymethamphetamine (MDMA or ecstasy) users report mild depressive symptoms. J. Psychopharmacol. 2001, 15:181-186.
89. Malberg J.E., Seiden L.S. Small changes in ambient temperature cause large changes in 3,4-methylenedioxymethamphetamine (MDMA)- induced serotonin neurotoxicity and core body temperature in the rat. J. Neurosci. 1998, 18:5086-5094.
90. Matthews A.J., Bruno R. An investigation of factors associated with depressive symptoms among a sample of regular ecstasy consumers. Neuropsychobiology 2010, 61:215-222.
91. McCann U.D., Ricaurte G.A. Effects of (+/-) 3, 4-methylenedioxymethamphetamine (MDMA) on sleep and circadian rhythms. Sci. World J. 2007, 7:231-238.
92. McCann U.D., Ricaurte G.A. Lasting neuropsychiatric sequelae of (+-) Methylenedioxymethamphetamine ('Ecstasy') in recreational users. J. Clin. Psychopharmacol. 1991, 11:302-305.
93. McCann U.D., Szabo Z., Scheffel U., Dannals R.F., Ricaurte G.A. Positron emission tomographic evidence of toxic effect of MDMA (Ecstasy") on brain serotonin neurones in human beings. Lancet 1998, 352:1433-1437.
94. McCann U.D., Szabo Z., Seckin E., Rosenblatt P., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB. Neuropsychopharmacology 2005, 30:1741-1750.
95. McCann U.D., Szabo Z., Vranesic M., Palermo M., Mathews W.B., Ravert H.T., Dannals R.F., Ricaurte G.A. Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine (ecstasy") users: relationship to cognitive performance. Psychopharmacology (Berl) 2008, 200:439-450.
96. McCann U.D., Sgambati F.P., Schwartz A.R., Ricaurte G.A. Sleep apnea in young abstinent recreational MDMA (ecstasy") consumers. Neurology 2009, 73:2011-2017.
97. McCann U.D., Edwards R.R., Smith M.T., Kelley K., Wilson M., Sgambati F., Ricaurte G. Altered pain responses in abstinent (±)3,4-methylenedioxymethamphetamine (MDMA, ecstasy") users. Psychopharmacology (Berl) 2011, 217:475-484.
98. McCann U.D., Mertl M., Eligulashvili V., Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology 1999, 143:417-425.
99. McElhatton P.R., Bateman D.N., Evans C., Pughe K.R., Thomas S.H. Congenital anomalies after prenatal ecstasy exposure. Lancet 1999, 354:1441-1442.
100. Mejias S., Rossignol M., Debatisse D., Streel E., Servais L., Guerit J.M., Philippot P., Campanella S. Event-related potentials in ecstasy (MDMA) users during a visual oddball task. Biol. Psychol. 2005, 69:333-352.
101. Meneses A. 5-HT system and cognition. Neurosci. Biobehav. Rev. 1999, 23:1111-1125.
102. Meneses A., Perez-Gracia G., Ponce-Lopez T., Tellez R., Castillo C. Serotonin transporter and memory. Neuropharmacol 2011, 61:355-363.
103. Merrill J. Ecstasy and neurodegeneration. Br. Med. J. 1996, 313:423.
104. Milani R.M., Parrott A.C., Schifano F., Turner J.J.D. Patterns of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum. Psychopharmacol. 2005, 20:1-13.
105. Mithoefer M.C., Wagner M.T., Mithoefer A.T., Jerome L., Doblin R. The safety and efficacy of+-3,4-methylenedioxymethamphetamine assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J. Psychopharmacol. 2011, 25:439-452.
106. Moeller F.G., Steinberg J.L., Dougherty D.M., Narayana P.A., Kramer L.A., Renshaw P.F. Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) 2004, 177:185-194.
107. Mohamed W.M., Ben Hamida S., Cassel J.C., de Vasconcelos A.P., Jones B.C. MDMA: interactions with other psychoactive drugs. Pharmacol. Biochem. Behav. 2011, 99:759-774.
108. Montgomery C., Hatton N.P., Fisk J.E., Ogden R.S., Jansari A. Assessing the functional significance of ecstasy-related memory deficits using a virtual reality paradigm. Hum. Psychopharmacol. 2010, 25:318-325.
109. Morefield K.M., Keane M., Felgate P., White J.M., Irvine R.J. The acute psychobiological impacts of illicit 3,4-methylenedioxymethamphetamine (MDMA, 'Ecstasy') consumption in recreational environments. Neuropsychobiology 2009, 60:216-217.
110. Morgan M.J. Memory deficits associated with recreational use of ecstasy" (MDMA). Psychopharmacology (Berl) 1999, 141:30-36.
111. Morgan M.J. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology (Berl) 2000, 152:230-248.
112. Morgan M.J., McFie L., Fleetwood L.H., Robinson J.A. Ecstasy (MDMA): are the psychological problems associated with its use reversed by prolonged abstinence?. Psychopharmacology (Berl) 2002, 159:294-303.
113. Murphy P.N., Wareing M., Fisk J.E., Montgomery C. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 2009, 60:159-175.
114. Murphy P.N., Bruno R., Ryland I., Wareing M., Fisk J.E., Montgomery C., Hilton J. The effects of 'ecstasy' (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses. Hum. Psychopharmacol. 2012, 27:113-138.
115. Nulsen C.E., Fox A.M., Hammond G.R. Differential effects of ecstasy on short-term and working memory: a meta-analysis. Neuropsychol. Rev. 2010, 20:21-32.
116. Olausson H., Charron J., Marchand S., Villemure C., Strigo I.A., Bushnell M.C. Feelings of warmth correlate with neural activity in right anterior insular cortex. Neurosci. Lett. 2005, 389:1-5.
117. O'Regan M.C., Clow A. Decreased pain tolerance and mood in recreational users of MDMA. Psychopharmacology (Berl) 2004, 173:446-451.
118. Parrott A.C. Human research on MDMA (3,4-methylenedioxymethamphetamine) neurotoxicity: cognitive and behavioural indices of change. Neuropsychobiology 2000, 42:17-24.
119. Parrott A.C. Human psychopharmacology of Ecstasy (MDMA): a review of fifteen years of empirical research. Hum. Psychopharmacol. 2001, 16:557-577.
120. Parrott A.C. Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol. Biochem. Behav. 2002, 71:837-844.
121. Parrott A.C. Cognitive deficits and cognitive normality in recreational cannabis and Ecstasy/MDMA users. Hum. Psychopharmacol. 2003, 18:89-90.
122. Parrott A.C. MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy: the neuropsychobiological implications of taking it at dances and raves. Neuropsychobiology 2004, 50:329-335.
123. Parrott A.C. Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy. J. Psychopharmacol. 2005, 19:71-83.
124. Parrott A.C. MDMA in humans: factors which affect the neuropsychobiological profiles of recreational Ecstasy users, the integrative role of bio-energetic stress. J. Psychopharmacol. 2006, 20:147-163.
125. Parrott A.C. The psychotherapeutic potential of MDMA (3,4-methylenedioxymethamphetamine): an evidence-based review. Psychopharmacology (Berl) 2007, 191:181-193.
126. Parrott A.C. Cortisol and MDMA (3,4-methylenedioxymethamphetamine): neurohormonal aspects of bioenergetic-stress in Ecstasy users. Neuropsychobiology 2009, 60:148-158.
127. Parrott A.C. Conscious awareness versus optimistic beliefs in recreational Ecstasy/MDMA users. New Horizons in the Neuroscience of Consciousness 2009, vol. 60:148-158. John Benjamins, Amsterdam.
128. Parrott A.C. Residual neurocognitive features of Ecstasy use: a reinterpretation of Halpern et al. (2011) consistent with serotonergic neurotoxicity. Addiction 2011, 106:1365-1368.
129. Parrott A.C. MDMA and temperature: a review of the thermal effects of 'Ecstasy' in humans. Drug Alcohol Depend. 2012, 121:1-9.
130. Parrott A.C. MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. Br. J. Pharmacol. 2012, 166:1518-1520.
131. Parrott A.C. Human psychobiology of MDMA or 'Ecstasy': an overview of 25 years of empirical research. Human Psychopharmacol. 2013, (in press).
132. Parrott A.C., Lasky J. Ecstasy (MDMA) effects upon mood and cognition; before, during, and after a Saturday night dance. Psychopharmacology (Berl) 1998, 139:261-268.
133. Parrott A.C., Lees A., Garnham N.J., Jones M., Wesnes K. Cognitive performance in recreational users of MDMA or ecstasy: evidence for memory deficits. J. Psychopharmacol. 1998, 12:79-83.
134. Parrott A.C., Sisk E., Turner J.J.D. Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alc. Depend. 2000, 60:105-110.
135. Parrott A.C., Milani R.M., Parmar R., Turner J.J.D. Recreational Ecstasy/MDMA and other drug users form the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology (Berl) 2001, 159:77-82.
136. Parrott A.C., Buchanan T., Scholey A.B., Heffernan T.M., Ling J., Rodgers J. Ecstasy attributed problems reported by novice, moderate and heavy recreational users. Hum. Psychopharmacol. 2002, 17:309-312.
137. Parrott A., Morinan A., Moss M., Scholey A. Understanding Drugs and Behaviour 2004, Wiley, Chichester.
138. Parrott A.C., Rodgers J., Buchanan T., Ling J., Heffernan T., Scholey A.B. Dancing hot on ecstasy: physical activity and thermal comfort ratings are associated with the memory and other psychobiological problems of recreational MDMA users. Hum. Psychopharmacol. 2006, 21:285-298.
139. Parrott A.C., Milani R.M., Gouzoulis-Mayfrank E., Daumann J. Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine): an analysis of their neuropsychobiological interactions in recreational users. J. Neural Trans. 2007, 114:959-968.
140. Parrott A.C., Lock J., Conner A.C., Kissling C., Thome J. Dance clubbing on MDMA and during abstinence from Ecstasy/MDMA: prospective neuroendocrine and psychobiological changes. Neuropsychobiology 2008, 57:165-180.
141. Patel M.M., Belson M.G., Longwater A.B., Olson K.R., Miller M.A. Methylenedioxymethamphetamine (ecstasy)-related hyperthermia. J. Emerg. Med. 2005, 29:451-454.
142. Peroutka S.J. 'Ecstasy': a human neurotoxin?. Arch. Gen. Psychiatry 1989, 46:191.
143. Puerta E., Hervias I., Aguirre N. On the mechanisms underlying 3,4-methylenedioxymethamphetamine toxicity: the dilemma of the chicken and the egg. Neuropsychobiology 2009, 60:119-129.
144. Quednow B.B., Kuhn K.U., Hoenig K., Maier W., Wagner M. Prepulse inhibition and habituation of acoustic startle response in male MDMA ('Ecstasy') users, cannabis users, and healthy controls. Neuropsychopharmacology 2004, 29:982-990.
145. Reay J.L., Hamilton C., Kennedy D.O., Scholey A.B. MDMA polydrug users show process-specific central executive impairments coupled with impaired social and emotional judgement processes. J. Psychopharmacol. 2006, 20:385-388.
146. Redfearn P.J., Agrawal N., Mair L.H. An association between the use of 3,4-methylenedioxymethamphetamine (ecstasy") and excessive wear of teeth. Addiction 1998, 93:745-748.
147. Rendell P.G., Gray T.J., Henry J.D., Tolan A. Prospective memory impairment in ecstasy" (MDMA) users. Psychopharmacology (Berl) 2007, 194:497-504.
148. Reneman L., Booij J., Majoie C.B.L., van den Brink W., den Heeten G.J. Investigating the potential neurotoxicity of ecstasy (MDMA): an imaging approach. Hum. Psychopharmacol. 2001, 16:579-588.
149. Reneman L., de Win M.M., van den Brink W., Booij J., den Heeten GJ Neuroimaging findings with MDMA/ecstasy: technical aspects, conceptual issues and future prospects. J. Psychopharmacol. 2006, 20:164-175.
150. Reid L.W., Elifson K.W., Sterk C.E. Hug drug or thug drug? Ecstasy use and aggressive behavior. Violence Vict. 2007, 22:104-119.
151. Ricaurte G.A., Bryan G., Strauss L., Seiden L.S., Schuster C.R. Hallucinogenic amphetamine selectively destroys brain serotonin nerve terminals. Science 1985, 229:986-988.
152. Ricaurte G.A., Yuan J., McCann U.D. (+-)-3,4-Methylenedioxymethamphetamine (MDMA, ecstasy) - induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 2000, 42:5-10.
153. Rizzo M., Lamers C.T.J., Sauer C.G., Ramaekers J.G., Bechara A., Anderson G.J. Impaired perception of self-motion (heading) in abstinent ecstasy and marijuana users. Psychopharmacology (Berl) 2005, 179:559-566.
154. Roberts G.M., Nestor L., Garavan H. Learning and memory deficits in ecstasy users and their neural correlates during a face-learning task. Brain Res. 2009, 1292:71-81.
155. Rodgers J. Cognitive performance amongst recreational users of ecstasy". Psychopharmacology (Berl) 2000, 151:19-24.
156. Rodgers J., Buchanan T., Scholey A.B., Heffernan T.M., Ling J., Parrott A.C. Patterns of drug use and the influence of gender on self reports of memory ability in ecstasy users: a web based study. J. Psychopharmacol. 2003, 17:379-386.
157. Rodgers J., Buchanan T., Heffernan T., Ling J., Scholey A. 'Ecstasy use, by itself, does not result in residual neurotoxicity'- a powerful argument?. Addiction 2011, 106:1369-1370.
158. Rogers G., Elston J., Garside R., Roome C., Taylor R., Younger P., Zawada A., Somerville M. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol. Assess. 2009, 13:1-315.
159. Roiser J.P., Cook L.J., Cooper J.D., Rubinsztein D.C., Sahakian B.J. Association of a functional polymorphism in the serotonin transporter gene with abnormal emotional processing in ecstasy users. Am. J. Psychiatry 2005, 162:609-612.
160. Roiser J.P., Sahakian B.J. Relationship between ecstasy use and depression: a study controlling for poly-drug use. Psychopharmacology 2004, 173:411-417.
161. Rugani F., Bacciardi S., Rovai L., Pacini M., Maremmani A.G.I., Deltito J., Dell'Osso L., Maremmani I. Symptomatological features of patients with and without Ecstasy use during their first psychotic episode. Int. J. Res. Public Health 2012, 9:2283-2292.
162. Sala M., Braida D. Endocannabinoids and 3,4-methylenedioxymethamphetamine (MDMA) interaction. Pharmacol. Biochem. Behav. 2005, 81:407-416.
163. Schifano F., Magni G. MDMA ('ecstasy') abuse: psychopathological features and craving for chocolate: a case series. Biol. Psychiatry 1994, 36:763-767.
164. Schifano F., Di Furia L., Forza G., Minicuci N., Bricolo R. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alc. Depend. 1998, 52:85-90.
165. Schifano F. Potential human neurotoxicity of MDMA ('ecstasy'): subjective self-reports, evidence form an Italian drug addiction centre and clinical case studies. Neuropsychobiology 2000, 42:25-33.
166. Schilt T., de Win M.M., Koeter M., Jager G., Korf D.J., van den Brink W., Schmand B. Cognition in novice ecstasy users with minimal exposure to other drugs: a prospective cohort study. Arch. Gen. Psychiatry 2007, 64:728-736.
167. Schmidt C.J. Neurotoxicity of the psychedelic amphetamine methylenedioxymethamphetamine. J. Pharmacol. Exp. Therap. 1987, 240:1-7.
168. Scholey A.B., Parrott A.C., Buchanan T., Heffernan T., Ling J., Rodgers J. Increased intensity of Ecstasy and polydrug usage in the more experienced recreational Ecstasy/MDMA users: a www study. Addict. Behav. 2004, 29:743-752.
169. Scholey A.B., Owen L., Gates J., Rodgers J., Buchanan T., Ling J., Heffernan T., Swan P., Stough C., Parrott A.C. Hair MDMA samples are consistent with reported Ecstasy use: findings from an internet study investigating effects of Ecstasy on mood and memory. Neuropsychobiology 2011, 63:15-21.
170. Semple D.M., Ebmeier K.P., Glabus M.F., O'Carroll R.E., Johnstone E.C. Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users. Br. J. Psychiatry 1999, 175:63-69.
171. Seger D. Cocaine, metamfetamine, and MDMA abuse: the role and clinical importance of neuroadaptation. Clin. Toxicol. 2010, 48:695-708.
172. Shulgin A.T. The background and chemistry of MDMA. J. Psychoact. Drugs 1986, 18:291-304.
173. Singer L.T., Moore D.G., Fulton S., Goodwin J., Turner J.J., Min M.O., Parrott A.C. Neurobehavioral outcomes of infants exposed to MDMA (Ecstasy) and other recreational drugs during pregnancy. Neurotoxicol. Teratol. 2012, 34:303-310.
174. Singer L.T., Moore D.G., Min M.O., Goodwin J., Turner J.J., Fulton S., Parrott A.C. One-Year Outcomes of Prenatal Exposure to MDMA and Other Recreational Drugs. Pediatrics 2012, 130:407-413.
175. Singer L.T., Moore D.G., Min M.O., Goodwin J., Turner J.J.T., Fulton S., Parrott A.C. Longitudinal outcomes of MDMA (Ecstasy)-exposed infants in the United Kingdom. College on Problems of Drug Dependence, 75th Annual Meeting 2013.
176. Soar K., Parrott A.C., Turner J.J.D. Persistent neuropsychological problems after seven years of abstinence from recreational Ecstasy (MDMA): a case study. Psychol. Rep. 2004, 95:192-196.
177. Steele T.D., McCann U.D., Ricaurte G.A. 3,4-methylenedioxymethamphetamine (MDMA, ecstasy"): pharmacology and toxicology in animals and humans. Addiction 1994, 89:539-551.
178. Stone D.M., Merchant K.M., Hanson G.R., Gibb J.W. Immediate and long-term effects of 3,4-methylenedioxymethamphetamine on serotonin pathways in brain of rat. Neuropharmacology 1987, 26:1677-1683.
179. Stough C., Downey L.A., King R., Papafotiou K., Swann P., Ogden E. The acute effects of 3,4-methylenedioxymethamphetamine and methamphetamine on driving: a simulator study. Accid. Anal. Prev. 2012, 45:493-497.
180. Thomasius R., Petersen K., Buchert R., Andresen B., Zapletalova P., Wartberg L., Nebeling B., Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users. Psychopharmacology (Berl) 2003, 167:85-96.
181. Thomasius R., Zapletalova P., Petersen K., Buchert R., Andresen B., Wartberg L., Nebeling B., Schmoldt A. Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J. Psychopharmacol. 2006, 20:211-225.
182. Topp L., Hando J., Dillon P., Roche A., Solowij N. Ecstasy use in Australia: patterns of use and associated harm. Drug Alc. Depend. 1999, 55:105-115.
183. Tuchtenhagen F., Daumann J., Norra C., Gobbelé R., Becker S., Pelz S., Sass H., Buchner H., Gouzoulis-Mayfrank E. High intensity dependence of auditory evoked dipole source activity indicates decreased serotonergic activity in abstinent ecstasy (MDMA) users. Neuropsychopharmacology 2011, 22:608-617.
184. Turner J.J.D., Nicolas L., Parrott A.C. Reduced calorie intake in the week following weekend MDMA (ecstasy) use. J. Psychopharmacol. 1998, 12. a43.
185. Verheyden S.L., Henry J.A., Curran H.V. Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum. Psychopharmacol. 2003, 18:507-517.
186. Verheyden S.L., Maidment R., Curran H.V. Quitting ecstasy: an investigation of why people stop taking the drug and their subsequent mental health. J. Psychopharmacol. 2003, 17:371-378.
187. Verkes R.J., Gigsman H.J., Pieters M.S.M., Schoemaker R.C., de Visser S., Kuijpers M. Cognitive performance and serotonergic function in users of Ecstasy. Psychopharmacology (Berl) 2001, 53:196-202.
188. Wagner D., Becker B., Koester P., Gouzoulis-Mayfrank E., Daumann J. A prospective study of learning, memory, and executive function in new MDMA users. Addiction 2013, 108:136-145.
189. Wasik A.M., Gandy M.N., McLldowie M., Holder M.J., Chamba A., Challa A., Lewis K.D., Young S.P., Scheel-Toellner D., Dyer M.J., Barnes N.M., Piggott M.J., Gordon J. Enhancing the anti-lymphoma potential of 3,4-methylenedioxymethamphetamine ('ecstasy') through iterative chemical redesign: mechanisms and pathways to cell death. Invest. New Drugs 2011, 30:1471-1483.
190. Watkins T.J., Raj V., Lee J., Dietrich M.S., Cao A., Blackford J.U., Salomon R.M., Park S., Benningfield M.M., Di Iorio C.R., Cowan R.L. Human ecstasy (MDMA) polydrug users have altered brain activation during semantic processing. Psychopharmacology (Berl) 2013, 227:41-54.
191. Weinborn M., Woods S.P., Nulsen C., Park K. Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval. J. Clin. Exp. Neuropsychol. 2012, 33:1119-1128.
192. Wetherell M.A., Atherton K., Grainger J., Brosnan R., Scholey A.B. The effect of multitasking on psychological stress reactivity in recreational users of cannabis and MDMA. Hum. Psychopharmacol. 2012, 27:167-176.
193. Wilson M.A., Ricaurte G.A., Molliver M.E. Distinct morphologic classes of serotonergic axons in primates exhibit differential vulnerability to the psychotropic drug 3,4-methylenedioxymethamphetamine. Neuroscience 1989, 28:121-137.
194. Yip J., Lee T. The effects of ecstasy use on neuropsychological function: a study in Hong Kong. Psychopharmacology (Berl) 2005, 179:620-628.
195. Zakzanis K.K., Young D.A. Memory impairment in abstinent MDMA (ecstasy) users: A longitudinal investigation. Neurology 2001, 56:966-969.
196. Zakzanis K.K., Campbell Z. Memory impairment in now abstinent MDMA users and continued users: a longitudinal follow-up. Neurology 2006, 66:740-741.
197. Zhou J.F., Chen P., Zhou Y.H., Zhang L., Chen H.H. 3,4-methylenedioxymethamphetamine abuse may cause oxidative stress and potential free radical damage. Free Radical Res. 2003, 37:491-497.